AstraZeneca Stock Drops 9% After Heart Drug Trial Fails
AstraZeneca is the UK's largest drugmaker. It worked with Ionis Pharmaceuticals to develop a heart drug called Wainua.
The drug failed its late-stage clinical trial. It did not work better than a placebo.
The trial tested Wainua against a rare heart condition. That condition is caused by abnormal protein buildup in the heart.
The trial ran for 140 weeks. After the news AstraZeneca's stock dropped 9%.
The company lost about $27 billion in market value. Both companies plan to share full trial results in August 2026.
Klear Note — Late-stage drug trials test if medicines work better than placebo. Failed trials mean the drug likely won't get approved for patients. Stock drops when investors worry about company profits.
Key Terms 4
- clinical trial A test on humans to see if a drug is safe and works
- placebo A fake pill with no medicine used to compare against real drugs
- market value The total worth of a company based on its share price
- Phase III trial The final large-scale test before a drug can be approved